Is Standard Biotools Stock a Good Investment?
Standard Biotools Investment Advice | LAB |
- Examine Standard Biotools' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Standard Biotools' leadership team and their track record. Good management can help Standard Biotools navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Life Sciences Tools & Services space and any emerging trends that could impact Standard Biotools' business and its evolving consumer preferences.
- Compare Standard Biotools' performance and market position to its competitors. Analyze how Standard Biotools is positioned in terms of product offerings, innovation, and market share.
- Check if Standard Biotools pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Standard Biotools' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Standard Biotools stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Standard Biotools is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Excited | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Standard Biotools Stock
Researching Standard Biotools' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 73.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.97. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Standard Biotools has Price/Earnings To Growth (PEG) ratio of 0.31. The entity recorded a loss per share of 0.52. The firm had not issued any dividends in recent years. Standard Biotools had a split on the 6th of December 2001.
To determine if Standard Biotools is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Standard Biotools' research are outlined below:
| Standard Biotools generated a negative expected return over the last 90 days | |
| Standard Biotools has high historical volatility and very poor performance | |
| Standard Biotools may become a speculative penny stock | |
| The company reported the last year's revenue of 174.43 M. Reported Net Loss for the year was (138.88 M) with profit before taxes, overhead, and interest of 84.26 M. | |
| Standard Biotools has about 81.31 M in cash with (143.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 73.0% of the company shares are owned by institutional investors | |
| Latest headline from prnewswire.com: ANY LAB TEST NOW Enters Entrepreneur Magazines Prestigious Franchise 500 Hall of Fame |
Standard Biotools Quarterly Liabilities And Stockholders Equity |
|
Standard Biotools uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Standard Biotools. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Standard Biotools' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Standard Biotools' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Standard Biotools' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-26 | 2024-12-31 | -0.03 | -0.0494 | -0.0194 | 64 | ||
2024-10-30 | 2024-09-30 | -0.09 | -0.07 | 0.02 | 22 | ||
2013-02-12 | 2012-12-31 | -0.16 | -0.14 | 0.02 | 12 | ||
2019-05-02 | 2019-03-31 | -0.25 | -0.28 | -0.03 | 12 | ||
2012-11-07 | 2012-09-30 | -0.21 | -0.18 | 0.03 | 14 | ||
2012-08-07 | 2012-06-30 | -0.25 | -0.22 | 0.03 | 12 | ||
2024-07-31 | 2024-06-30 | -0.08 | -0.12 | -0.04 | 50 | ||
2021-11-08 | 2021-09-30 | -0.22 | -0.18 | 0.04 | 18 |
Standard Biotools' market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 458.57 M.Market Cap |
|
Standard Biotools' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.31) | |
| Return On Capital Employed | (0.32) | (0.34) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.29) | (0.31) |
Determining Standard Biotools' profitability involves analyzing its financial statements and using various financial metrics to determine if Standard Biotools is a good buy. For example, gross profit margin measures Standard Biotools' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Standard Biotools' profitability and make more informed investment decisions.
Please note, the presentation of Standard Biotools' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Standard Biotools' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Standard Biotools' management manipulating its earnings.
Evaluate Standard Biotools' management efficiency
Standard Biotools has Return on Asset of (0.1801) % which means that on every $100 spent on assets, it lost $0.1801. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.4375) %, meaning that it generated no profit with money invested by stockholders. Standard Biotools' management efficiency ratios could be used to measure how well Standard Biotools manages its routine affairs as well as how well it operates its assets and liabilities. As of March 24, 2025, Return On Tangible Assets is expected to decline to -0.31. In addition to that, Return On Capital Employed is expected to decline to -0.34. At present, Standard Biotools' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 26.1 M, whereas Non Current Assets Total are forecasted to decline to about 131.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.34 | 1.40 | |
| Tangible Book Value Per Share | 0.94 | 0.99 | |
| Enterprise Value Over EBITDA | (4.10) | (4.31) | |
| Price Book Value Ratio | 1.31 | 2.02 | |
| Enterprise Value Multiple | (4.10) | (4.31) | |
| Price Fair Value | 1.31 | 2.02 | |
| Enterprise Value | 376.6 M | 274.1 M |
Evaluating the management effectiveness of Standard Biotools allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Standard Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta 1.616 |
Basic technical analysis of Standard Stock
As of the 24th of March, Standard Biotools has the Variance of 35.72, risk adjusted performance of (0.07), and Coefficient Of Variation of (1,149). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Standard Biotools, as well as the relationship between them.Standard Biotools' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Standard Biotools insiders, such as employees or executives, is commonly permitted as long as it does not rely on Standard Biotools' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Standard Biotools insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Standard Biotools' Outstanding Corporate Bonds
Standard Biotools issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Standard Biotools uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Standard bonds can be classified according to their maturity, which is the date when Standard Biotools has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Standard Biotools' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Standard Biotools' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.29) | |||
| Mean Deviation | 4.19 | |||
| Coefficient Of Variation | (1,149) | |||
| Standard Deviation | 5.98 | |||
| Variance | 35.72 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.41) | |||
| Total Risk Alpha | (0.08) | |||
| Treynor Ratio | (0.30) | |||
| Maximum Drawdown | 40.74 | |||
| Value At Risk | (9.29) | |||
| Potential Upside | 6.21 | |||
| Skewness | 1.39 | |||
| Kurtosis | 5.65 |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.29) | |||
| Mean Deviation | 4.19 | |||
| Coefficient Of Variation | (1,149) | |||
| Standard Deviation | 5.98 | |||
| Variance | 35.72 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.41) | |||
| Total Risk Alpha | (0.08) | |||
| Treynor Ratio | (0.30) | |||
| Maximum Drawdown | 40.74 | |||
| Value At Risk | (9.29) | |||
| Potential Upside | 6.21 | |||
| Skewness | 1.39 | |||
| Kurtosis | 5.65 |
Consider Standard Biotools' intraday indicators
Standard Biotools intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Standard Biotools stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Standard Biotools time-series forecasting models is one of many Standard Biotools' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Standard Biotools' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Standard Stock media impact
Far too much social signal, news, headlines, and media speculation about Standard Biotools that are available to investors today. That information is available publicly through Standard media outlets and privately through word of mouth or via Standard internal channels. However, regardless of the origin, that massive amount of Standard data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Standard Biotools news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Standard Biotools relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Standard Biotools' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Standard Biotools alpha.
Standard Biotools Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Standard Biotools can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Standard Biotools Corporate Management
| Jeffrey Black | Chief Officer | Profile | |
| Shane Bowen | Chief Officer | Profile | |
| Elizabeth Jensen | Chief Officer | Profile | |
| Mark Spearman | Sr Communications | Profile | |
| Dr Dphil | CoFounder Board | Profile | |
| Peter DeNardo | Investor Relations | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. If investors know Standard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Standard Biotools listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share | Quarterly Revenue Growth (0.14) | Return On Assets | Return On Equity |
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Standard Biotools' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Standard Biotools is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Standard Biotools' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.